N-Myc Proto-Oncogene Protein
-
Subject Areas on Research
- A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
- An improved method for bivariate meta-analysis when within-study correlations are unknown.
- CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer.
- Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.
- Genetic variation associated with childhood and adult stature and risk of MYCN-amplified neuroblastoma.
- Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
- Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.
- Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report.
- MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis.
- MYCN amplification drives an aggressive form of spinal ependymoma.
- N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
- Neuroblastoma in a pediatric patient with a microduplication of 2p involving the MYCN locus.
- Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma.
- Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).
- Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer.
- Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.